THARTharimmune, Inc.

Nasdaq hillstreambio.com


$ 3.50 $ 0.01 (0.3 %)    

Friday, 14-Jun-2024 10:22:40 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 3.35
$ 3.50
$ 0.00 x 0
$ 0.00 x 0
$ 3.50 - $ 3.50
$ 2.75 - $ 163.09
120,376
na
2.63M
$ 0.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-22-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-14-2022 03-31-2022 10-Q
10 04-01-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-tharimmune-thar-shares-are-getting-hammered

Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into a...

Core News & Articles

- Form 8-K

 why-tharimmune-thar-shares-are-moving

Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.

Core News & Articles

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developi...

Core News & Articles

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug...

 tharimmunes-oral-under-the-cheek-candidate-at-par-with-fda-approved-injectable-with-potential-for-chronic-liver-disease

Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential ...

Core News & Articles

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous...

Core News & Articles

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavaila...

Core News & Articles

Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe c...

 perspective-therapeutics-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or c...

Core News & Articles

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching in...